DGD 201
Alternative Names: DGD-201Latest Information Update: 15 Dec 2023
At a glance
- Originator Deargen
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Diffuse large B cell lymphoma
Most Recent Events
- 12 Dec 2023 Early research in Diffuse large B cell lymphoma in South Korea (unspecified route) (Deargen pipeline, December 2023)